News &amp; Updates

The changes seen in left heart geometry may be used as a marker to predict the development of new-onset atrial fibrillation (NOAF) in patients with hypertension, suggests a study.

Left heart geometry changes predict NOAF hypertensive patients

28 Dec 2024

$Osteoporotic fractures tied to death, allograft loss in kidney transplant recipients$

Osteoporotic fractures tied to death, allograft loss in kidney transplant recipients

Osteoporotic fractures do not occur frequently among kidney transplant recipients but when they do, they contribute to increased risks of death and allograft loss, according to a retrospective cohort study.

Osteoporotic fractures tied to death, allograft loss in kidney transplant recipients

Luspatercept transforming the management of β-thalassaemia

β-thalassaemia, an inherited haemoglobin disorder, affects approximately 1.5 percent of the global population, with 60,000 symptomatic individuals born annually, predominantly in low- and middle-income countries. [Orphanet J Rare Dis 2010;5:11]

Luspatercept transforming the management of β-thalassaemia

Rezvilutamide + ADT delivers improved outcomes for mHSPC patients regardless of age

The combination of rezvilutamide plus androgen-deprivation therapy (ADT) proves to be efficacious and well-tolerated in the treatment of patients with high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC) across all age groups, according to a post hoc analysis of the phase III CHART trial.

Rezvilutamide + ADT delivers improved outcomes for mHSPC patients regardless of age

Volatile organic compounds up hypertension risk

A recent study has found epidemiological evidence pointing to an association between environmental pollutants and hypertension. This finding calls attention to the contribution of nonoccupational volatile organic compounds (VOCs) to the risk of hypertension in the general population.

Volatile organic compounds up hypertension risk

27 Dec 2024

Mitapivat cuts transfusion burden in TD thalassaemia

In adults with transfusion-dependent (TD*) α- or β-thalassaemia, mitapivat, a first-in-class, oral, allosteric activator of pyruvate kinase, significantly reduces transfusion burden, with durable responses up to 36 weeks, findings from the phase III ENERGIZE-T study have shown.

Mitapivat cuts transfusion burden in TD thalassaemia

KEYNOTE-811: Add-on pembrolizumab improves OS in HER2+ gastroesophageal cancer

Adding pembrolizumab to trastuzumab and chemotherapy significantly improves overall survival (OS) in patients with advanced unresectable or metastatic HER2+ gastric/gastroesophageal junction (G/GEJ) adenocarcinoma and in those with PD-L1 CPS ≥1, according to the protocol-specified final OS analysis of the KEYNOTE-811 trial presented at ESMO Asia 2024.

KEYNOTE-811: Add-on pembrolizumab improves OS in HER2+ gastroesophageal cancer

New UC guideline endorses early use of advanced therapies

The American Gastroenterological Association (AGA), in an update to its living practice guideline, recommends the early use of advanced therapies for the pharmacological management of moderate-to-severe ulcerative colitis (UC) in adult outpatients.

New UC guideline endorses early use of advanced therapies

Hitting OS endpoint reaffirms frontline daratumumab-VCd as SoC for AL amyloidosis

The evidence supporting an upfront daratumumab-containing regimen as the SoC for AL amyloidosis is reaffirmed by the significant OS benefit demonstrated in the final analysis of ANDROMEDA

Hitting OS endpoint reaffirms frontline daratumumab-VCd as SoC for AL amyloidosis